Inhibition of covid-19 virus by multiple-component formulations
AssigneeAnkh Life Sciences Limited
InventorsGene H. ZAID, Cameron E. WEST, Robert Preston MOORE, Jason H. WEST
Life of this patent
Estimating the term…
Abstract
Formulations for treatment of human subjects exposed to, or potentially exposed to SARS-CoV-2 virus, or suffering from COVID-19, comprising a multiple-component antiviral formulation comprising a curcumin component, harmine component, and isovanillin component, and/or variants thereof. The formulation may also be used to inhibit SARS-CoV-2 virus in cell-based assays or in the manufacture of antiviral medicaments.
Claims15
A multiple-component antiviral formulation comprising a mixture of a curcumin component, a harmine component, and an isovanillin component, and/or the isomers, tautomers, enantiomers, esters, derivatives, metal complexes, prodrugs, solvates, metabolites, and pharmaceutically acceptable salts of any or all of the foregoing, for use in inhibiting replication of SARS-CoV-2 virus in a subject in need thereof.
An antiviral medicament for treatment or prophylaxis of a human subject suffering from COVID-19 comprising a mixture of a curcumin component, a harmine component, and an isovanillin component, and/or the isomers, tautomers, enantiomers, esters, derivatives, metal complexes, prodrugs, solvates, metabolites, and pharmaceutically acceptable salts of any or all of the foregoing.
Use of a multiple-component antiviral formulation comprising a mixture of a curcumin component, a harmine component, and an isovanillin component, and/or the isomers, tautomers, enantiomers, esters, derivatives, metal complexes, prodrugs, solvates, metabolites, and pharmaceutically acceptable salts of any or all of the foregoing, for inhibition of replication of SARS-CoV-2 virus in a subject in need thereof, or for the treatment of a human subject exposed to or suffering from COVID-19.
Dependencies are inferred from the claim text.